BRIEF published on 04/07/2026 at 07:05, 6 months ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 6 months ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 6 months 17 days ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
PRESS RELEASE published on 03/21/2026 at 10:05, 6 months 17 days ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 8 months 26 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
BRIEF published on 12/02/2025 at 07:05, 10 months 5 days ago Aelis Farma launches a Phase 2B clinical trial for AEF0217 in people with Down syndrome Clinical Trial Aelis Farma CB1-SSi AEF0217 Down Syndrome
BRIEF published on 09/25/2025 at 22:20, 1 year ago Availability of the 2025 half-year financial report by Aelis Farma Financial Report Biopharmaceuticals Aelis Farma Medical Innovations CB1-SSi
PRESS RELEASE published on 09/25/2025 at 22:15, 1 year ago Half yearly financial reports and audit reports/limited reviews / Terms of availability of the half-yearly financial report Aelis Farma announces availability of 2025 half-year financial report. Company specializes in CB1 receptor treatments for brain and peripheral diseases Financial Report Aelis Farma CB1 Receptor Brain Diseases Peripheral Diseases
BRIEF published on 07/31/2024 at 10:02, 2 years 2 months ago Aelis Farma successfully raises 4.5 million euros Euronext Paris Investors Fundraising Biopharmaceutical Aelis Farma
PRESS RELEASE published on 07/31/2024 at 09:57, 2 years 2 months ago Inside Information / Other news releases Aelis Farma successfully completes Reserved Offering, raising €4.5 million for drug development. CEO expresses gratitude to investors. New shares to be admitted for trading on Euronext Paris on Aug 2, 2024 Euronext Paris Capital Increase Drug Development Aelis Farma Reserved Offering
Published on 10/07/2026 at 23:30, 4 hours 12 minutes ago Algo Grande Copper Core Testing Shows Mineralized Skarn is Denser and More Chargeable Than Host Rocks; Ground Gravity Survey to Begin at Adelita
Published on 10/07/2026 at 22:05, 5 hours 37 minutes ago Loar Holdings Inc. Announces Date and Time for Third Quarter 2026 Earnings and Conference Call
Published on 10/07/2026 at 17:00, 10 hours 42 minutes ago BlackBerry Radar Expands Asset Intelligence Platform with Dynamic Pairing
Published on 10/07/2026 at 15:30, 12 hours 12 minutes ago Gold Port Announces Marketing Agreement with NAI Interactive Ltd.
Published on 10/07/2026 at 14:30, 13 hours 12 minutes ago Secure Blockchain's Agentic Solutions Signs Financial Services Firm, Expanding Enterprise AI Into Corporate Finance
Published on 10/07/2026 at 23:30, 4 hours 12 minutes ago Acuity Analytics expands US data and technology capabilities with acquisition of Continuus
Published on 10/07/2026 at 23:20, 4 hours 22 minutes ago BAR LEONE, HONG KONG, IS THE WORLD'S BEST BAR AS THE LIST OF THE 50 BEST BARS 2026 IS REVEALED
Published on 10/07/2026 at 22:00, 5 hours 42 minutes ago Invitation - Q3 2026 Trading Update Conference Call
Published on 10/07/2026 at 21:35, 6 hours 7 minutes ago OCI N.V. Notes Enterprise Chamber Decision Not to Order Inquiry
Published on 10/07/2026 at 20:55, 6 hours 47 minutes ago innoscripta SE Initiates Independent External Investigations to Clarify the Facts Underlying the Authorities’ Investigations and Review Clusterix’s Documentation and Control Mechanisms
Published on 10/07/2026 at 18:19, 9 hours 22 minutes ago Outstanding shares and voting rights statement at 30 September 2026
Published on 10/07/2026 at 17:45, 9 hours 57 minutes ago Availability of the Pre-Q3 2026 Sales Communication
Published on 10/07/2026 at 15:54, 11 hours 48 minutes ago Disclosure of Share Capital and Voting Rights as of September 30, 2026
Published on 10/07/2026 at 08:15, 19 hours 27 minutes ago EURAZEO TO ACQUIRE MIYA WATER, A GLOBAL SPECIALIST IN EFFICIENT WATER MANAGEMENT SOLUTIONS
